Apr 3, 2009 by Brian Orelli, PhDGilead: Helping Investors Cope With the MarketDiversifying seems to be paying off for the drugmaker.
Apr 2, 2009 by Brian Orelli, PhDA Diabetic CompromiseBristol-Myers and AstraZeneca will have to test their drug after it goes on the market.
Apr 2, 2009 by Brian Orelli, PhDMonsanto Rounds Up Alternative GrowthForget Roundup. The agri-giant has a better plan.
Apr 1, 2009 by Brian Orelli, PhDConservative Celgene's ConundrumIt's not an earnings miss, but it hurts nonetheless.
Mar 31, 2009 by Brian Orelli, PhDPharma's Refreshing Bad NewsRefreshing? Bad? Should those words really be in the same description?
Mar 31, 2009 by Brian Orelli, PhDDestiny for Diabetes DrugsA two-day FDA panel should get the blood (sugar) flowing.
Mar 31, 2009 by Brian Orelli, PhDA Good Start for a Potential BlockbusterAfinitor's FDA approval is nice, but it needs another indication to be a blockbuster.
Mar 31, 2009 by Brian Orelli, PhD5 Highly Rated Stocks in the RedEarnings aren't all they're cracked up to be.
Mar 31, 2009 by Brian Orelli, PhDAmylin Smacks Down the CompetitionAmylin's once-weekly Byetta trounces the competition.
Mar 30, 2009 by Brian Orelli, PhDHere's Some Cash. Go Away.The FTC doesn't like that kind of attitude.
Mar 30, 2009 by Brian Orelli, PhDTo the Moon, Crestor?More data from AstraZeneca's Jupiter study pops up.
Mar 30, 2009 by Brian Orelli, PhDChange the Game? Change the Rules!Ways to get around Obama's plan to lower health care costs.
Mar 30, 2009 by Brian Orelli, PhDHopes Fall Short for Arena PharmaceuticalsSometimes, meeting primary goals isn't enough.
Mar 30, 2009 by Brian Orelli, PhDBoston Scientific Is Abbott's Sweat MopWiping the floor with its competitor.
Mar 27, 2009 by Brian Orelli, PhDThe Skinny on a Triple-Decker UpdateAmylin's public relations department might need to go on a diet.
Mar 27, 2009 by Brian Orelli, PhDTrading Up With the $95 From GenentechGenentech is gone; here's what you should replace it with.
Mar 27, 2009 by Brian Orelli, PhDDyax: A Cinderella Story Ends in a FallFDA asks Dyax for more information.
Mar 26, 2009 by Brian Orelli, PhDR&D Your Way to Higher SalesBiogen is trying to lower side effects to increase sales.
Mar 25, 2009 by Brian Orelli, PhDYou Can't Have One Without the OtherHeath insurers are playing fair.
